Colon Cancer – Stage III
Sponsor: Easton Cooperative Group (ECOG)
Phase III
Randomized Trial of Standard chemotherapy alone or combined with atezolizumab as adjuvant Therapy for patients with stage III colon cancer and deficient DNA mismatch repair
Eligibility Criteria:
- Histologically proven Stage III colon adenocarcinoma
- Completely resected tumors
- Entire tumor in colon
- No residual of lymph node involvement or metastatic disease
- No active autoimmune disease, including colitis, panhypopituitarism, adrenal insufficiency
- No known active hepatitis B or C infection
- No active pulmonary disease with hypoxia
To learn more about available clinical research trials contact:
Deborah Brunetti, RN, CRC
Hunterdon Regional Cancer Center – Research Department
2100 Wescott Drive
Flemington, NJ 08822
908-237-2330 option #3